Coloplast offers a rare quality-healthcare entry point: resilient chronic-care franchises, U.S. share upside and Kerecis recovery could drive substantial five-year value despite temporary margin and regulatory pressure.
Overview
Coloplast is a global medical-technology leader whose five businesses serve chronic, intimate healthcare needs through prescription products, hospital tenders and direct-to-consumer channels. More than 75% of sales come from daily chronic-care consumables, supporting resilient demand and high retention. Its moat is visible in global market shares of 35%–40% in Ostomy Care and 40%–45% in Continence Care, with U.S. expansion offering substantial runway. Nine-month FY 2025/26 organic revenue growth was 6%, while reported revenue of DKK 21,482 million rose 3% because FX created a 3-percentage-point headwind. EBIT before special items was DKK 5,599 million, with a 26.1% margin, temporarily depressed by FX, Kerecis integration and Costa Rica and Portugal ramp-up costs. **The core business remains profitable and cash generative**, producing DKK 4,093 million of nine-month FCF, or 20.0% of sales. **The principal catalyst is normalization of Kerecis and factory economics**, with management guiding to 5%–6% organic growth and approximately 15% ROIC for FY 2025/26. At DKK 438.30, valuation is challenged on trailing P/E but attractive on 16.1x–17.6x forward P/E if earnings recover; the report’s probability-weighted five-year target is DKK 1,084.80.